A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).

BMC Cancer · 2020 · PMC7268477 · PMID 32487038

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

The high lesional control rates seen with SABR, in conjunction with its modest side effect profile, have since resulted in an increasing trend to treat oligometastatic lesions in an attempt to improve overall survival (OS) and progression free survival (PFS), delay initiation of systemic therapies with unfavorable toxicity profiles, and offer treatment breaks for individuals amassing toxicity from systemic therapy [ 7 ].

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.